Announcements Trials
Browse Landscape

Phase

Phase 3 10Phase 2 8Phase 4 4Phase NA 3Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Classical hematology 1

Conditions

Venous Thrombosis 1Venous Thromboembolism 1Pulmonary Embolism 1Lung Neoplasms 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × Dalteparin × Clear all
NCT02334007 2018-09-18

Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery

McMaster University

Phase 1/2 Completed
102 enrolled
Classical hematologyThoracic

Lung Neoplasms, Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡